search
Back to results

Efficiency of a Small-peptide Enteral Feeding Formula Compared to a Whole-protein Formula (NUTRI_REA)

Primary Purpose

Traumatic and/or Non-traumatic Brain Injury, Critically Ill

Status
Unknown status
Phase
Phase 4
Locations
France
Study Type
Interventional
Intervention
Peptamen® AF
Sondalis® HP
Sponsored by
Centre Hospitalier Universitaire de Besancon
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Traumatic and/or Non-traumatic Brain Injury

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Admission in our surgical critical care unit.
  • Traumatic brain injury.
  • Non-traumatic brain injury: stroke, intracranial and/or subarachnoid hemorrhage, subdural and/or extradural hematoma.
  • Expected duration of mechanical ventilation > 48 hours.

Exclusion Criteria:

  • Abdominal surgery in the previous 30 days.
  • Pregnancy.
  • Breast-feeding.
  • Hemodynamic instability defined as infusion of norepinephrine > 3 mg/h, or epinephrine > 1 mg/h, or as increasing needs in vasopressive or inotropic drugs.

Sites / Locations

  • Surgical Critical Care Unit, CHRU Jean MinjozRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

Sondalis® HP

Peptamen® AF

Arm Description

The Control Group that will receive Sondalis ® HP (a whole-peptide formula).

In this arm, patients have enteral nutrition with Peptamen® AF

Outcomes

Primary Outcome Measures

the nutritional efficacy of a small-peptide (Peptamen AF®) to that of a whole-protein (Sondalis HP®) enteral feeding formula in traumatic and non-traumatic brain injured critically ill patients
To compare the nutritional efficacy of a small-peptide (Peptamen AF®) to that of a whole-protein (Sondalis HP®) enteral feeding formula in traumatic and non-traumatic brain injured critically ill patients.

Secondary Outcome Measures

impact on morbidity and mortality of a small-peptide (Peptamen AF®) to that of a whole-protein (Sondalis HP®) enteral feeding formula.

Full Information

First Posted
February 10, 2013
Last Updated
August 4, 2016
Sponsor
Centre Hospitalier Universitaire de Besancon
Collaborators
Nestlé Foundation
search

1. Study Identification

Unique Protocol Identification Number
NCT01833624
Brief Title
Efficiency of a Small-peptide Enteral Feeding Formula Compared to a Whole-protein Formula
Acronym
NUTRI_REA
Official Title
Efficiency and Tolerance of a Small-peptide Enteral Feeding Formula Compared to a Whole-protein Formula in the Critically Ill Patient : a Prospective Randomized Trial
Study Type
Interventional

2. Study Status

Record Verification Date
August 2016
Overall Recruitment Status
Unknown status
Study Start Date
June 2012 (undefined)
Primary Completion Date
May 2017 (Anticipated)
Study Completion Date
August 2017 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Centre Hospitalier Universitaire de Besancon
Collaborators
Nestlé Foundation

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
An early and efficient enteral nutritional support could improve the clinical outcomes of brain injured critically ill patients. Gastrointestinal feeding intolerance defined as an increased gastric residual volume frequently occurs in these patients. Previous experimental studies have suggested that a small-peptide enteral feeding formula could promote the gastric emptying compared to a whole-protein formula. An improved gastrointestinal tolerance of enteral nutrition should allow a rapid increase in the daily caloric intake and enhance nutritional support of brain injured critically ill patients.
Detailed Description
This open-labelled prospective randomized trial aims to compare 2 groups of patients: the Study Group and the Control Group. The randomization process will concern the allocation of the type of enteral feeding formula administered for nutritional support: Peptamen® AF in the Study Group, and Sondalis® HP in the Control Group. 2 centers are involved in this study. Each patient admitted in the critical care unit will be assessed for eligibility. After written informed consent is obtained from relatives, patient without any exclusion criteria will be included in the study. The allocation of the type of enteral nutritional feeding formula will be randomized after inclusion. Enteral nutrition according to the randomization group will start within the 48 hours of admission and up to 10 days, if requested. Beyond the 10th day, all patients will receive standard enteral nutrition formula. After inclusion, data regarding efficacy and tolerance will be assessed daily up to day 10. Mortality and outcome will be assessed at day 28 and at day 60.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Traumatic and/or Non-traumatic Brain Injury, Critically Ill

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
206 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Sondalis® HP
Arm Type
Active Comparator
Arm Description
The Control Group that will receive Sondalis ® HP (a whole-peptide formula).
Arm Title
Peptamen® AF
Arm Type
Experimental
Arm Description
In this arm, patients have enteral nutrition with Peptamen® AF
Intervention Type
Dietary Supplement
Intervention Name(s)
Peptamen® AF
Intervention Description
Comparison of two types of enteral nutrition feeding: Peptamen® AF and Sondalis® HP
Intervention Type
Dietary Supplement
Intervention Name(s)
Sondalis® HP
Primary Outcome Measure Information:
Title
the nutritional efficacy of a small-peptide (Peptamen AF®) to that of a whole-protein (Sondalis HP®) enteral feeding formula in traumatic and non-traumatic brain injured critically ill patients
Description
To compare the nutritional efficacy of a small-peptide (Peptamen AF®) to that of a whole-protein (Sondalis HP®) enteral feeding formula in traumatic and non-traumatic brain injured critically ill patients.
Time Frame
Day3 to Day5
Secondary Outcome Measure Information:
Title
impact on morbidity and mortality of a small-peptide (Peptamen AF®) to that of a whole-protein (Sondalis HP®) enteral feeding formula.
Time Frame
Day 10

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Admission in our surgical critical care unit. Traumatic brain injury. Non-traumatic brain injury: stroke, intracranial and/or subarachnoid hemorrhage, subdural and/or extradural hematoma. Expected duration of mechanical ventilation > 48 hours. Exclusion Criteria: Abdominal surgery in the previous 30 days. Pregnancy. Breast-feeding. Hemodynamic instability defined as infusion of norepinephrine > 3 mg/h, or epinephrine > 1 mg/h, or as increasing needs in vasopressive or inotropic drugs.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Anne-Sophie BALON
Phone
+3381668675
Email
annesophie.balon@gmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Gilles Blasco
Official's Role
Principal Investigator
Facility Information:
Facility Name
Surgical Critical Care Unit, CHRU Jean Minjoz
City
Besançon
ZIP/Postal Code
25030
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Anne-Sophie BALON
Phone
+3381668675
Email
annesophie.balon@gmail.com
First Name & Middle Initial & Last Name & Degree
Gilles Blasco

12. IPD Sharing Statement

Learn more about this trial

Efficiency of a Small-peptide Enteral Feeding Formula Compared to a Whole-protein Formula

We'll reach out to this number within 24 hrs